Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...
Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback